StrokeEspertaMenteNCT07504692
Biodiversity and Human Functioning Following Acquired Cerebrovascular Lesions - Phase 1
An observational study of Stroke, run by Dr. Franco Molteni at 3 sites in Italy.
Trial summary
The study aims to investigate the impact that the set of factors to which a post-stroke person is exposed during daily life can have on their health. The study will examine the totality of conditions, known as the "exposome," which include biological, environmental, social, and lifestyle factors. Read more about this study
- Who is it for?
- Ages 5 years and older
- Conditions the study is for
- Stroke
- How many people
- 150 participants
- Where
- 3 sitesItaly
- Study dates
- 26 Mar 2025to 30 Nov 2025
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 5 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: post-stroke patients
Who may be able to join
- Subjects with Cerebral Stroke, both ischemic and hemorrhagic, in either pediatric or adult age;
- Age > 5 years
- Absence of ongoing clinical acute conditions
- Able to provide written informed consent to participate in the study if of legal age, or consent from a legal representative if a minor
- Absence of major psychiatric disorders associated with the disability condition
Who cannot join
- Inability to provide informed consent
- Presence of other neurological conditions (e.g. Multiple Sclerosis, Parkinson's Disease…)
- Presence of ongoing clinical acute conditions
- Presence of major psychiatric disorders associated with the disability condition
Trial locations and contacts
3 sites in 1 country.
Italy3 sites
IRCCS Scientific Institute E. Medea
Bosisio Parini, Lecco, 23842
Villa Beretta Rehabilitation Center
Costa Masnaga, Lecco, 23845
IRCCS Fondazione Don Carlo Gnocchi
Milan, Milano, 20148
About this study
Official title: Esposoma: Biodiversità e Human Functioning Post Lesioni Vascolari Cerebrali Acquisite
The study aims to investigate the impact that the set of factors to which a post-stroke person is exposed during daily life can have on their health. The study will examine the totality of conditions, known as the "exposome," which include biological, environmental, social, and lifestyle factors.
Read the detailed description
The exposome represents the complex set of environmental conditions to which an individual is exposed throughout their entire life, including factors such as light, atmospheric pollutants, diet, lifestyles, stress, and interpersonal relationships that are closely correlated with the environmental context and the social network in which and with which the person lives (e.g., rural/metropolitan context, presence or absence of a caregiver) (D'Errico et al., 2023).
The WHO evaluates health in bio-psycho-social terms to arrive at the concept of human functioning and "lived health" (Bickenbach et al., 2023), meaning the ability to carry out daily activities and social participation with the best possible personal and environmental interaction. Studies correlating the exposome with human functioning outcomes in post-stroke patients are extremely limited to date. Indeed, most clinical scales assess the motor, cognitive, and relational abilities of the individual and their impact on quality of life, but the socio-environmental interactions of the individual (e.g., sociodemographic, psychological factors, and living environment) are not systematically included in the analysis (Fahey et al., 2018).
Among the elements of the exposome to be considered, the dual patient-caregiver relationship plays an absolutely central role, as does the environmental context in which patient and caregiver express relationships and activities through which they give form and meaning to emotions, intentions, and resulting actions that shape behaviors and lifestyles.
For all these reasons, it is necessary to redefine multifactorial outcome measures that quantify and qualify relevant aspects of the exposome in an integrated way.
Urbanization and the varying geographical context of residence also carry significant weight in the exposome. "Rural" settings generally allow for greater experience of biodiversity with natural environments and greater exposure to natural light, positively influencing circadian rhythms with antidepressant effects potentially comparable to pharmacological treatments (Burgess et al., 2010). Equally important are contexts that facilitate social relationships, with the potential to significantly and positively influence the psychological well-being of individuals and their perceived sense of happiness (Beccetti et al., 2023). "Metropolitan" contexts, on the other hand, are characterized by environmental situations that may include sources of light pollution, which is associated with a higher risk of psychiatric disorders (Nature 2023, editorial), reduced air quality - associated with obesity and metabolic problems in children (Maitre et al., 2022) - as well as other environmental constraints such as architectural barriers and a fragmented human relational fabric that lead to restrictions or impoverishment of social participation.
Unfavorable environmental conditions can also negatively influence mechanisms of inflammation and systemic immunity (Vieujean S., 2022). Numerous data show that inflammation affects the nervous system both indirectly and through the disruption of slow-wave sleep phases (Gerhard et al., 2000; Block et al., 2005), with consequent alterations in brain plasticity (Facchin et al., 2020) and functional recovery. The combined analysis of inflammation and EEG in post-stroke patients can provide fundamental data for better understanding the role played by the environment in the reconfiguration of functional networks. In particular, inflammasomes, the Natural Killer immune response, cortisol, melatonin, and catecholamine concentrations, neurotrophic factors in peripheral extracellular vesicles of astrocytic origin (ADEVs), single nucleotide polymorphisms (SNPs), and microRNAs can provide information individually or in combination with EEG-based slow-wave sleep detection.
These findings suggest that the exposome and biodiversity may have a determining impact through components that can influence human functioning, with evident potential consequences for the lived health conditions of post-stroke individuals and their caregivers. Biodiversity, which can also be expressed through varied multisensory stimulation, can induce changes in the lifestyle of the individual and their immediate social network, consequently modifying human functioning and creating the bio-psycho-social conditions essential for maintaining and enhancing the results achieved through rehabilitation processes in stroke patients.
In particular, correlations between exposure to both natural and artificial light and modifications in neurophysiological, functional, and biological responses - investigated in numerous studies - suggest its prominent role in both the internal and external exposome (McGlashan et al., 2021; Sabbah et al., 2022).
The limitations of existing studies and the limited exploration of the impact the exposome may have on rehabilitation outcomes in post-stroke patients define an important scientific context to be systematically explored, in order to create new models for evaluating the health status derived from integrated multimodal rehabilitation processes. The challenges that future research will need to address are: i) the adoption of an interdisciplinary approach; ii) the introduction of multifactorial bio-psycho-social analyses; iii) the study of heterogeneous patient populations across the lifespan, with specific reference to developmental age; iv) the inclusion, recognition, and analysis of the role and lived experience of caregivers.
- Conditions
- Stroke
- Keywords
- Caregiver, Human Functioning, Environment, Biomarkers, Exposome
- Medical subject headings
- Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Post stroke patients in chronic condition | The study will include patients with post-stroke outcomes and their caregivers. Patients with ischemic or hemorrhagic stroke outcomes will be included, divided into age groups: a) 30 pediatric stroke patients (age < 18 years at the time of the acute event) ; b) 120 stroke patients (60 patients aged ≤ 65 years at the time of the acute event, 60 patients aged > 65 years at the time of the acute event). Of these, 40 patients will be 10 years post acute event, 40 patients will be 5 years post acute event, and 40 will be recruited from patients hospitalized for a recent stroke event. The selected population will be representative of the general population of patients with post-stroke disabilities, reflecting their biodiversity in terms of sex, age, ethnicity, educational level, socioeconomic conditions, and level of motor and cognitive impairment. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Motor measures
10 metres walking test: 10mWT (lower values better performance)
Measured: Baseline
Motor measure
6 minutes walking test: 6mWT (higher values better performance)
Measured: Baseline
Motor Measure
Timed Up and Go test: TUG (lower values better performance)
Measured: Baseline
Motor measure
Berg balance scale: BBS (0-56 higher values better performance)
Measured: Baseline
motor outcome measure
Functional Ambulation Category: FAC (0-5 higher values better performance)
Measured: Baseline
Cognitive measure
MoCa Test: MOCA (0-30 higher values better performance)
Measured: Baseline
Secondary outcomes (9)
Biomarkers from blood samples
cortisol
Measured: Baseline
Biomarkers from blood samples
melatonin
Measured: Baseline
Biomarkers from blood samples
catecholamines
Measured: Baseline
Biomakers from blood samples
genetic polymorphisms
Measured: baseline
Biomarkers from blood samples
inflammatory cytokines
Measured: Baseline
Patients' reported outcome
WHODAS (0-100 higher values worse disability)
Measured: Baseline
Patient's reported outcome
Stroke Impact Scale: SIS (0-100 higher values better condition)
Measured: Baseline
Patient's reported outcome
Fatigue Impact Scale: FIS (0-160 lower values better condition)
Measured: Baseline
Patient's reported outcome
Pittsburgh Scale: PSQI (0-21 lower values better sleep quality)
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Apr 2026
- Study start26 Mar 2025
- Primary completion30 Sep 2025
- Study completion30 Nov 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for StrokeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 150 participants (actual)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Dr. Franco Molteni
- Sponsor type
- University, hospital or other
- Collaborators
- IRCCS Eugenio Medea, Fondazione Don Carlo Gnocchi ETS
- Responsible party
- Sponsor-investigator, Dr. Franco Molteni, Villa Beretta Rehabilitation Center
- Investigators
- Franco Molteni, MD, Study chair, Villa Beretta Rehabilitation Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07504692
- Sponsor's protocol ID
- Espertamente Fase1
- Acronym
- EspertaMente
- Status last verified
- Mar 2026
- First submitted
- 5 Mar 2026
- Last updated
- 14 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Esposoma: Biodiversità e Human Functioning Post Lesioni Vascolari Cerebrali Acquisite
- ClinicalTrials.gov ID
- NCT07504692
- Acronym / sponsor ID
- EspertaMente / Espertamente Fase1
- Conditions
- Stroke
- Keywords
- Caregiver, Human Functioning, Environment, Biomarkers, Exposome
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 150 participants (actual)
- Lead sponsor
- Dr. Franco MolteniUniversity, hospital or other
- Collaborators
- IRCCS Eugenio Medea, Fondazione Don Carlo Gnocchi ETS
- Study start
- 26 Mar 2025 (actual)
- Primary completion
- 30 Sep 2025 (actual)
- Study completion
- 30 Nov 2025 (actual)
- First posted
- 1 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study aims to investigate the impact that the set of factors to which a post-stroke person is exposed during daily life can have on their health. The study will examine the totality of conditions, known as the "exposome," which include biological, environmental, social, and lifestyle factors.
Detailed description
The exposome represents the complex set of environmental conditions to which an individual is exposed throughout their entire life, including factors such as light, atmospheric pollutants, diet, lifestyles, stress, and interpersonal relationships that are closely correlated with the environmental context and the social network in which and with which the person lives (e.g., rural/metropolitan context, presence or absence of a caregiver) (D'Errico et al., 2023).
The WHO evaluates health in bio-psycho-social terms to arrive at the concept of human functioning and "lived health" (Bickenbach et al., 2023), meaning the ability to carry out daily activities and social participation with the best possible personal and environmental interaction. Studies correlating the exposome with human functioning outcomes in post-stroke patients are extremely limited to date. Indeed, most clinical scales assess the motor, cognitive, and relational abilities of the individual and their impact on quality of life, but the socio-environmental interactions of the individual (e.g., sociodemographic, psychological factors, and living environment) are not systematically included in the analysis (Fahey et al., 2018).
Among the elements of the exposome to be considered, the dual patient-caregiver relationship plays an absolutely central role, as does the environmental context in which patient and caregiver express relationships and activities through which they give form and meaning to emotions, intentions, and resulting actions that shape behaviors and lifestyles.
For all these reasons, it is necessary to redefine multifactorial outcome measures that quantify and qualify relevant aspects of the exposome in an integrated way.
Urbanization and the varying geographical context of residence also carry significant weight in the exposome. "Rural" settings generally allow for greater experience of biodiversity with natural environments and greater exposure to natural light, positively influencing circadian rhythms with antidepressant effects potentially comparable to pharmacological treatments (Burgess et al., 2010). Equally important are contexts that facilitate social relationships, with the potential to significantly and positively influence the psychological well-being of individuals and their perceived sense of happiness (Beccetti et al., 2023). "Metropolitan" contexts, on the other hand, are characterized by environmental situations that may include sources of light pollution, which is associated with a higher risk of psychiatric disorders (Nature 2023, editorial), reduced air quality - associated with obesity and metabolic problems in children (Maitre et al., 2022) - as well as other environmental constraints such as architectural barriers and a fragmented human relational fabric that lead to restrictions or impoverishment of social participation.
Unfavorable environmental conditions can also negatively influence mechanisms of inflammation and systemic immunity (Vieujean S., 2022). Numerous data show that inflammation affects the nervous system both indirectly and through the disruption of slow-wave sleep phases (Gerhard et al., 2000; Block et al., 2005), with consequent alterations in brain plasticity (Facchin et al., 2020) and functional recovery. The combined analysis of inflammation and EEG in post-stroke patients can provide fundamental data for better understanding the role played by the environment in the reconfiguration of functional networks. In particular, inflammasomes, the Natural Killer immune response, cortisol, melatonin, and catecholamine concentrations, neurotrophic factors in peripheral extracellular vesicles of astrocytic origin (ADEVs), single nucleotide polymorphisms (SNPs), and microRNAs can provide information individually or in combination with EEG-based slow-wave sleep detection.
These findings suggest that the exposome and biodiversity may have a determining impact through components that can influence human functioning, with evident potential consequences for the lived health conditions of post-stroke individuals and their caregivers. Biodiversity, which can also be expressed through varied multisensory stimulation, can induce changes in the lifestyle of the individual and their immediate social network, consequently modifying human functioning and creating the bio-psycho-social conditions essential for maintaining and enhancing the results achieved through rehabilitation processes in stroke patients.
In particular, correlations between exposure to both natural and artificial light and modifications in neurophysiological, functional, and biological responses - investigated in numerous studies - suggest its prominent role in both the internal and external exposome (McGlashan et al., 2021; Sabbah et al., 2022).
The limitations of existing studies and the limited exploration of the impact the exposome may have on rehabilitation outcomes in post-stroke patients define an important scientific context to be systematically explored, in order to create new models for evaluating the health status derived from integrated multimodal rehabilitation processes. The challenges that future research will need to address are: i) the adoption of an interdisciplinary approach; ii) the introduction of multifactorial bio-psycho-social analyses; iii) the study of heterogeneous patient populations across the lifespan, with specific reference to developmental age; iv) the inclusion, recognition, and analysis of the role and lived experience of caregivers.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Target follow-up
- 1 Day
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Post stroke patients in chronic condition | – | –The study will include patients with post-stroke outcomes and their caregivers. Patients with ischemic or hemorrhagic stroke outcomes will be included, divided into age groups: a) 30 pediatric stroke patients (age < 18 years at the time of the acute event) ; b) 120 stroke patients (60 patients aged ≤ 65 years at the time of the acute event, 60 patients aged > 65 years at the time of the acute event). Of these, 40 patients will be 10 years post acute event, 40 patients will be 5 years post acute event, and 40 will be recruited from patients hospitalized for a recent stroke event. The selected population will be representative of the general population of patients with post-stroke disabilities, reflecting their biodiversity in terms of sex, age, ethnicity, educational level, socioeconomic conditions, and level of motor and cognitive impairment. |
Who may qualify
- Ages
- 5 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- post-stroke patients
Key inclusion criteria (5 listed)
- Subjects with Cerebral Stroke, both ischemic and hemorrhagic, in either pediatric or adult age;
- Age > 5 years
- Absence of ongoing clinical acute conditions
- Able to provide written informed consent to participate in the study if of legal age, or consent from a legal representative if a minor
- Absence of major psychiatric disorders associated with the disability condition
Key exclusion criteria (4 listed)
- Inability to provide informed consent
- Presence of other neurological conditions (e.g. Multiple Sclerosis, Parkinson's Disease…)
- Presence of ongoing clinical acute conditions
- Presence of major psychiatric disorders associated with the disability condition
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Motor measures
Time frame: Baseline
10 metres walking test: 10mWT (lower values better performance)
Motor measure
Time frame: Baseline
6 minutes walking test: 6mWT (higher values better performance)
Motor Measure
Time frame: Baseline
Timed Up and Go test: TUG (lower values better performance)
Motor measure
Time frame: Baseline
Berg balance scale: BBS (0-56 higher values better performance)
motor outcome measure
Time frame: Baseline
Functional Ambulation Category: FAC (0-5 higher values better performance)
Cognitive measure
Time frame: Baseline
MoCa Test: MOCA (0-30 higher values better performance)
9 secondary outcomes
Biomarkers from blood samples
Time frame: Baseline
Biomarkers from blood samples
Time frame: Baseline
Biomarkers from blood samples
Time frame: Baseline
Biomakers from blood samples
Time frame: baseline
Biomarkers from blood samples
Time frame: Baseline
Patients' reported outcome
Time frame: Baseline
Patient's reported outcome
Time frame: Baseline
Patient's reported outcome
Time frame: Baseline
Patient's reported outcome
Time frame: Baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Stroke
Not yet recruiting
Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
Acute Ischemic Stroke
RecruitingObservational study
ELATE Study: Evaluating Large-vessel Acute Thrombectomy in Extended Time Window
Acute Ichemic Stroke
Recruiting
Web-Based Tele-Rehabilitation Using Action Observation and Mirror Therapy for Subacute Stroke: A Randomized Controlled Trial
Stroke, Upper Extremity Paresis
Recruiting
Early Motor-Cognitive Integrative Training on Cognitive and Motor Performance in Patients With Aneurysmal Subarachnoid Hemorrhage
Subarachnoid Aneurysm Hemorrhage
Not yet recruiting
Selective Intra-Arterial Hypothermia After Endovascular Treatment for Acute Basilar Artery Occlusion
Acute Ischemic Stroke, Basilar Artery Occlusion
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Franco Molteni, MD study chair
Villa Beretta Rehabilitation Center
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Stroke, run by Dr. Franco Molteni at 3 sites in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Motor measures (time frame: Baseline). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2026.